Natalia N. Makar'IAnts
Natalia N. Makar'IAnts has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- eVGeny i. ShMeleV
Federal State Budgetary Scientific Institution “Central Research Institute of Tuberculosis”, Ministry of Science and Higher Education of the Russian Federation
8 shared publications - Larisa N. Lepekha
Central Tuberculosis Research Institute
4 shared publications - Anna S. Zaytseva
Central Tuberculosis Research Institute
3 shared publications - Igor Evgenievich Tyurin
Russian Medical Academy of Continuous Professional Education
3 shared publications - Ilya V. Sivokozov
Federal State Budgetary Scientific Institution “Central Research Institute of Tuberculosis” of the Ministry of Science and Higher Education of the Russian Federation
3 shared publications - Natalia Yu. Kravchenko
The Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department
3 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Luchevaya Diagnostika in Journal of radiology and nuclear medicine
- Vol. 107 (3) , 158-164
A Case of Acute Respiratory Distress Syndrome in a Young Athlete
A case of a 26-year-old patient hospitalized with acute respiratory failure is presented. Clinical, laboratory, and radiological diagnostic (radiography, chest contrast-enhanced computed tomography, echocardiography) data were analyzed. Computed tomography revealed diffuse ground-glass opacities in the lungs, characteristic of diffuse alveolar damage. Acute respiratory distress syndrome (ARDS) secondary to fat embolism following intramuscular injection of an anabolic steroid with intravascular entry was diagnosed. Respiratory support and corticosteroid therapy were administered with positive dynamics. This observation demonstrates a rare cause of ARDS, which requires awareness among radiologists, pulmonologists, and intensivists.
- 29 October 2026
- Published by Luchevaya Diagnostika in Journal of radiology and nuclear medicine
- Vol. 107 (3) , 158-164
Open AccessA Case of Acute Respiratory Distress Syndrome in a Young Athlete
A case of a 26-year-old patient hospitalized with acute respiratory failure is presented. Clinical, laboratory, and radiological diagnostic (radiography, chest contrast-enhanced computed tomography, echocardiography) data were analyzed. Computed tomography revealed diffuse ground-glass opacities in the lungs, characteristic of diffuse alveolar damage. Acute respiratory distress syndrome (ARDS) secondary to fat embolism following intramuscular injection of an anabolic steroid with intravascular entry was diagnosed. Respiratory support and corticosteroid therapy were administered with positive dynamics. This observation demonstrates a rare cause of ARDS, which requires awareness among radiologists, pulmonologists, and intensivists.
- Open Access
- 14 July 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 106-112
Features of clinical and functional parameters in patients with interstitial lung diseases of various origin and diabetes mellitus
Introduction . Diabetes mellitus (DM) remains one of the most prevalent chronic diseases: as of October 2024, more than 5 million patients are registered in the country, predominantly with type 2 DM, while a substantial proportion of cases are identified only through active screening. In addition to traditional target organs, the lungs are considered a potentially vulnerable structure; however, pulmonary involvement in diabetes remains insufficiently studied. Current evidence indicates a higher prevalence of DM among patients with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis, yet the impact of diabetes as an independent condition on the course of ILD remains unclear. Aim. To determine the clinical and functional characteristics of patients with chronic interstitial lung diseases of various etiologies complicated by diabetes mellitus. Materials and м ethods . A cross-sectional retrospective–prospective cohort study including 126 patients was conducted. The main group (group 1) consisted of 70 patients with ILD and concomitant DM, while the comparison group (group 2) included 56 patients with ILD without diabetes. Inclusion criteria required the presence of DM as an independent disease entity. All patients underwent medical history assessment, radiographic archive analysis, a 6-minute walk test, body plethysmography, and evaluation of diffusing capacity of the lungs. Results . The groups were comparable in terms of sex, age, and nosological structure. Patients with combined pathology demonstrated longer disease duration, a higher prevalence of dyspnea and weakness, reduced exercise tolerance, more pronounced impairment in FEV₁ and diffusing capacity, and a greater need for intensive therapy. Conclusions . Diabetes mellitus has an adverse impact on clinical and functional parameters in patients with chronic ILDs.
- 14 July 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 106-112
Open AccessFeatures of clinical and functional parameters in patients with interstitial lung diseases of various origin and diabetes mellitus
Introduction . Diabetes mellitus (DM) remains one of the most prevalent chronic diseases: as of October 2024, more than 5 million patients are registered in the country, predominantly with type 2 DM, while a substantial proportion of cases are identified only through active screening. In addition to traditional target organs, the lungs are considered a potentially vulnerable structure; however, pulmonary involvement in diabetes remains insufficiently studied. Current evidence indicates a higher prevalence of DM among patients with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis, yet the impact of diabetes as an independent condition on the course of ILD remains unclear. Aim. To determine the clinical and functional characteristics of patients with chronic interstitial lung diseases of various etiologies complicated by diabetes mellitus. Materials and м ethods . A cross-sectional retrospective–prospective cohort study including 126 patients was conducted. The main group (group 1) consisted of 70 patients with ILD and concomitant DM, while the comparison group (group 2) included 56 patients with ILD without diabetes. Inclusion criteria required the presence of DM as an independent disease entity. All patients underwent medical history assessment, radiographic archive analysis, a 6-minute walk test, body plethysmography, and evaluation of diffusing capacity of the lungs. Results . The groups were comparable in terms of sex, age, and nosological structure. Patients with combined pathology demonstrated longer disease duration, a higher prevalence of dyspnea and weakness, reduced exercise tolerance, more pronounced impairment in FEV₁ and diffusing capacity, and a greater need for intensive therapy. Conclusions . Diabetes mellitus has an adverse impact on clinical and functional parameters in patients with chronic ILDs.
- 22 June 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (3)
Sarcoidosis: federal clinical guidelines 2025
Sarcoidosis is a systemic inflammatory disease of unknown etiology characterized by the formation of noncaseating granulomas, multisystem organ involvement, and T-cell activation at the site of granulomatous inflammation with the release of various chemokines and cytokines. The prevalence of sarcoidosis is 3 – 25 cases per 100,000 population. The mainstay of sarcoidosis therapy is corticosteroids, immunosuppressants, and drugs that affect oxidative stress and tumor necrosis factor. The aim of the article was to introduce the latest procedures for the diagnosis and treatment of sarcoidosis of various localizations, agreed upon in the Russian Federation. The target audience for these clinical guidelines are general practitioners, internists, pulmonologists, phthisiologists, pathologists, radiologists, and rehabilitation physicians. Methods. Each recommendation statement for diagnostic and therapeutic measures is assessed using evidence levels ranging from 1 to 5 and a recommendation strength rating scale for categories A, B, and C. The clinical guidelines also contain commentary and explanations for these recommendations, algorithms for the diagnosis and treatment of idiopathic pulmonary fibrosis, and reference materials. Conclusion. These clinical guidelines provide an overview of current knowledge on the etiology and pathogenesis, clinical manifestations, diagnosis, and treatment of sarcoidosis. These clinical guidelines were approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation in 2025.
- 22 June 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (3)
Sarcoidosis: federal clinical guidelines 2025
Sarcoidosis is a systemic inflammatory disease of unknown etiology characterized by the formation of noncaseating granulomas, multisystem organ involvement, and T-cell activation at the site of granulomatous inflammation with the release of various chemokines and cytokines. The prevalence of sarcoidosis is 3 – 25 cases per 100,000 population. The mainstay of sarcoidosis therapy is corticosteroids, immunosuppressants, and drugs that affect oxidative stress and tumor necrosis factor. The aim of the article was to introduce the latest procedures for the diagnosis and treatment of sarcoidosis of various localizations, agreed upon in the Russian Federation. The target audience for these clinical guidelines are general practitioners, internists, pulmonologists, phthisiologists, pathologists, radiologists, and rehabilitation physicians. Methods. Each recommendation statement for diagnostic and therapeutic measures is assessed using evidence levels ranging from 1 to 5 and a recommendation strength rating scale for categories A, B, and C. The clinical guidelines also contain commentary and explanations for these recommendations, algorithms for the diagnosis and treatment of idiopathic pulmonary fibrosis, and reference materials. Conclusion. These clinical guidelines provide an overview of current knowledge on the etiology and pathogenesis, clinical manifestations, diagnosis, and treatment of sarcoidosis. These clinical guidelines were approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation in 2025.
- 17 April 2026
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 2 (1)
Sarcoidosis. (Clinical guidelines. Short version)
This article presents a summary of the clinical guidelines «Sarcoidosis: Federal Clinical Guidelines for Diagnosis and Treatment», developed by five scientific and practical societies and approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation.
- 17 April 2026
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 2 (1)
Sarcoidosis. (Clinical guidelines. Short version)
This article presents a summary of the clinical guidelines «Sarcoidosis: Federal Clinical Guidelines for Diagnosis and Treatment», developed by five scientific and practical societies and approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation.
- Open Access
- 16 December 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (11) , 1049-1055
Adverse reactions in the treatment of patients with non-tuberculous lung mycobacterial pulmonary disease and the possibility of their solution
Aim. To study the adverse reactions that develop as a result of complex antibiotic therapy in patients with non-tuberculous lung mycobacterial (NTML) and to determine methods for their elimination without compromising the effectiveness of NTML treatment. Materials and methods. Examined 147 patients with confirmed NTML, for which they received treatment in accordance with the results of drug susceptibility of the pathogen. Before and during treatment, a study of clinical, biochemical blood tests, urinalysis, electrocardiogram, external respiration function, ultrasound of the abdominal organs and kidneys was performed. Results. Under the conditions of antimicrobial therapy (AMT) for non-tuberculous mycobacteriosis of the lungs, 41 (27.9%) patients developed adverse drug reaction (ADR). The most frequent adverse reactions were: allergic reactions in the form of urticaria, nausea, vomiting, arthralgia, nephro- and ototoxic reactions; 34 (82.9%) patients required treatment adjustment without discontinuation of AMT, and only in 7 (17.1%) cases, AMT was discontinued. A full course of multicomponent AMT was completed in 124 (84.4%) patients with NTML. An algorithm for monitoring therapy in NTML patients from the standpoint of preventing ADR has been developed. The categories of patients with potential risks of developing ADR under AMT were determined. Patients without the development of ADR had a positive radiological dynamics in 27.9% of cases, sputum conversion – in 42%. Patients with ADR had positive clinical dynamics in 39% of cases, radiological – in 31.7% of cases, sputum conversion – in 36.6% of cases. Conclusion. The incidence of ADR development remains high when complex AMT is administered to patients with NTML. The patient's comorbid background is the main risk factor for the development of ADR when prescribing multicomponent AMT. A multivariate analysis of the effectiveness of treatment in NTML patients showed comparable data among patients taking complex AMT and receiving only alternative therapies. The success of NTML treatment depends on a comprehensive personalized approach.
- 16 December 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (11) , 1049-1055
Open AccessAdverse reactions in the treatment of patients with non-tuberculous lung mycobacterial pulmonary disease and the possibility of their solution
Aim. To study the adverse reactions that develop as a result of complex antibiotic therapy in patients with non-tuberculous lung mycobacterial (NTML) and to determine methods for their elimination without compromising the effectiveness of NTML treatment. Materials and methods. Examined 147 patients with confirmed NTML, for which they received treatment in accordance with the results of drug susceptibility of the pathogen. Before and during treatment, a study of clinical, biochemical blood tests, urinalysis, electrocardiogram, external respiration function, ultrasound of the abdominal organs and kidneys was performed. Results. Under the conditions of antimicrobial therapy (AMT) for non-tuberculous mycobacteriosis of the lungs, 41 (27.9%) patients developed adverse drug reaction (ADR). The most frequent adverse reactions were: allergic reactions in the form of urticaria, nausea, vomiting, arthralgia, nephro- and ototoxic reactions; 34 (82.9%) patients required treatment adjustment without discontinuation of AMT, and only in 7 (17.1%) cases, AMT was discontinued. A full course of multicomponent AMT was completed in 124 (84.4%) patients with NTML. An algorithm for monitoring therapy in NTML patients from the standpoint of preventing ADR has been developed. The categories of patients with potential risks of developing ADR under AMT were determined. Patients without the development of ADR had a positive radiological dynamics in 27.9% of cases, sputum conversion – in 42%. Patients with ADR had positive clinical dynamics in 39% of cases, radiological – in 31.7% of cases, sputum conversion – in 36.6% of cases. Conclusion. The incidence of ADR development remains high when complex AMT is administered to patients with NTML. The patient's comorbid background is the main risk factor for the development of ADR when prescribing multicomponent AMT. A multivariate analysis of the effectiveness of treatment in NTML patients showed comparable data among patients taking complex AMT and receiving only alternative therapies. The success of NTML treatment depends on a comprehensive personalized approach.
- Open Access
- 5 September 2023
- Published by Reaviz Medical University in Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)
- Vol. 13 (5) , 137-141
Evolution of cavity formation in nontuberculosis mycobacteriosis of the lungs
The results of a long – term observation from practice are presented, which showed the gradual formation of the destruction cavity in a patient with limited focal and peribronchial fibrosis of the lung tissue. Patient H., 54 years old for more than twenty years, was observed by a pulmonologist at the place of residence with a diagnosis of chronic bronchitis with frequent annual exacerbations. She was admitted to the clinic of the FSBSI "CRIT" with complaints of pronounced weakness, fatigue, shortness of breath, prolonged subfebrile temperature mainly at night, cough with difficult-to-separate mucus of a mucous nature. A retrospective analysis of computed tomography of the chest revealed a consistent transformation of local focal peribronchial compaction in the middle lobe of the right lung into a limited area of bronchiectasia and the formation of a small cystic cavity with widespread zones of bilateral pneumonic infiltration. This observation shows the practical significance of CT research in understanding the mechanisms of formation of bronchiectatic cystic cavity in non-tuberculosis mycobacteriosis of the lungs.
- 5 September 2023
- Published by Reaviz Medical University in Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)
- Vol. 13 (5) , 137-141
Open AccessEvolution of cavity formation in nontuberculosis mycobacteriosis of the lungs
The results of a long – term observation from practice are presented, which showed the gradual formation of the destruction cavity in a patient with limited focal and peribronchial fibrosis of the lung tissue. Patient H., 54 years old for more than twenty years, was observed by a pulmonologist at the place of residence with a diagnosis of chronic bronchitis with frequent annual exacerbations. She was admitted to the clinic of the FSBSI "CRIT" with complaints of pronounced weakness, fatigue, shortness of breath, prolonged subfebrile temperature mainly at night, cough with difficult-to-separate mucus of a mucous nature. A retrospective analysis of computed tomography of the chest revealed a consistent transformation of local focal peribronchial compaction in the middle lobe of the right lung into a limited area of bronchiectasia and the formation of a small cystic cavity with widespread zones of bilateral pneumonic infiltration. This observation shows the practical significance of CT research in understanding the mechanisms of formation of bronchiectatic cystic cavity in non-tuberculosis mycobacteriosis of the lungs.
- Open Access
- 1 January 2023
- Published by NP Rusmedical Group in Doctor.Ru
- Vol. 22 (2)
Specificity of Therapy Selection for Patients with Nontuberculous Lung Mycobacteriosis
Aim: To identify the incidence and the characteristics of adverse reactions, to mitigate them, and to determine possible adjustments in antimicrobial therapy. Design: Observational retrospective long-term study. Materials and methods. We examined 125 patients with nontuberculous lung mycobacteriosis. 73.6% of cases had concomitant diseases. Results. The therapy for nontuberculous mycobacteriosis was prescribed in 115 patients, depending on drug susceptibility, and included at least 3 drug products. 31.3% of patients had adverse reactions; one third of these patients had allergic reactions. Hepatotoxic reactions were recorded in 16.5% of cases, cardiotoxic — in 12.2%, ototoxic — in 10.4%, optic neuritis was diagnosed in 5 % of cases. In 31.3% of cases, the therapy was adjusted, in 13.9% of cases, the therapy was reviewed and alternative treatment was offered. The complete antibacterial course was prescribed to 79 (68.7%) patients. Conclusion. The therapy for nontuberculous mycobacteriosis should be selected in inpatient settings with laboratory and functional monitoring. Keywords: nontuberculous lung mycobacteriosis, antimicrobial therapy, adverse reactions.
- 1 January 2023
- Published by NP Rusmedical Group in Doctor.Ru
- Vol. 22 (2)
Open AccessSpecificity of Therapy Selection for Patients with Nontuberculous Lung Mycobacteriosis
Aim: To identify the incidence and the characteristics of adverse reactions, to mitigate them, and to determine possible adjustments in antimicrobial therapy. Design: Observational retrospective long-term study. Materials and methods. We examined 125 patients with nontuberculous lung mycobacteriosis. 73.6% of cases had concomitant diseases. Results. The therapy for nontuberculous mycobacteriosis was prescribed in 115 patients, depending on drug susceptibility, and included at least 3 drug products. 31.3% of patients had adverse reactions; one third of these patients had allergic reactions. Hepatotoxic reactions were recorded in 16.5% of cases, cardiotoxic — in 12.2%, ototoxic — in 10.4%, optic neuritis was diagnosed in 5 % of cases. In 31.3% of cases, the therapy was adjusted, in 13.9% of cases, the therapy was reviewed and alternative treatment was offered. The complete antibacterial course was prescribed to 79 (68.7%) patients. Conclusion. The therapy for nontuberculous mycobacteriosis should be selected in inpatient settings with laboratory and functional monitoring. Keywords: nontuberculous lung mycobacteriosis, antimicrobial therapy, adverse reactions.
- Open Access
- 12 August 2022
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 94 (7) , 865-871
Data from the Russian Severe Asthma Registry (RSAR)
Aim. Creation of the "Russian register of patients with severe asthma" and obtaining data on the population characteristics of patients with severe asthma (SA), the prevalence of SA phenotypes, treatment outcomes and the degree of disease control. Materials and methods. Observational non-interventional study, which consists in the data analysis obtained on the basis of registration cards of the Russian Register of Patients with Severe Bronchial Asthma, data collection in which was carried out on the Oracle XE platform. Statistical data processing was carried out using Power BI, PSPP and Microsoft Excel spreadsheets. Results. The study included 4376 adult patients (mean age 60.613.5 years, 65% women) diagnosed with SA from 57 regions of Russia for the period from June 2018 to December 2021. T2 inflammation was detected in 94.8% of patients when determining blood eosinophils and IgE of blood serum; 69% of patients with SA corresponded to the allergic phenotype. 83.3% of patients had no control of BA and 53% had 1 or more exacerbations of BA per year. 8% of patients received systemic corticosteroids as a permanent therapy, while biologics 10.6%. Conclusion. The vast majority of adult patients with SA correspond to the T2 phenotype, have uncontrolled asthma with a high frequency of exacerbations and reduced lung function. A more favorable course of the disease was noted in patients receiving biological therapy, which requires appropriate measures to increase the possibility of access to this type of therapy.
- 12 August 2022
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 94 (7) , 865-871
Open AccessData from the Russian Severe Asthma Registry (RSAR)
Aim. Creation of the "Russian register of patients with severe asthma" and obtaining data on the population characteristics of patients with severe asthma (SA), the prevalence of SA phenotypes, treatment outcomes and the degree of disease control. Materials and methods. Observational non-interventional study, which consists in the data analysis obtained on the basis of registration cards of the Russian Register of Patients with Severe Bronchial Asthma, data collection in which was carried out on the Oracle XE platform. Statistical data processing was carried out using Power BI, PSPP and Microsoft Excel spreadsheets. Results. The study included 4376 adult patients (mean age 60.613.5 years, 65% women) diagnosed with SA from 57 regions of Russia for the period from June 2018 to December 2021. T2 inflammation was detected in 94.8% of patients when determining blood eosinophils and IgE of blood serum; 69% of patients with SA corresponded to the allergic phenotype. 83.3% of patients had no control of BA and 53% had 1 or more exacerbations of BA per year. 8% of patients received systemic corticosteroids as a permanent therapy, while biologics 10.6%. Conclusion. The vast majority of adult patients with SA correspond to the T2 phenotype, have uncontrolled asthma with a high frequency of exacerbations and reduced lung function. A more favorable course of the disease was noted in patients receiving biological therapy, which requires appropriate measures to increase the possibility of access to this type of therapy.
- Open Access
- 30 April 2022
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 32 (2) , 171-180-180
Нуреrsensitivity pneumonitis combined with arterial hypertension: clinical, radiological, functional features
The aim of the study was to explore the clinical, radiological, functional indicators of hypersensitivity pneumonitis (HP) in combination with arterial hypertension, to assess the effect of these diseases on each other.Methods. The study included 50 patients with hypersensitivity pneumonitis (HP) and 49 patients with arterial hypertension (AH). The patients were divided into three groups. The main group included 24 patients with hypersensitivity pneumonitis combined with AH. The comparison group was 26 patients with HP without AH; the control group was 25 patients with arterial hypertension alone. Clinical symptoms, radiological findings, and results of instrumental tests were analyzed.Results. The intensity of clinical symptoms (shortness of breath, cough) was significantly higher in the main group than in the control and comparison groups. Exercise tolerance estimated from the six-minute walk test was significantly lower in the main group. The clinical status correlated with the functional testResults. Volumetric and velocity spirometry values tended to decrease more in the main group compared to the other two groups. The lung diffusion capacity was significantly lower in the group of patients with HP in combination with AH compared to the group of patients with hypertension only. A similar trend was observed when assessing the chest CT: significantly more pronounced changes were found in the main group. EchoCG showed a significant increase in pulmonary hypertension and volumes of the right heart in the main group compared to the group of patients with AH alone.Conclusion. The present study provides evidence of the greater intensity of respiratory symptoms, decreased functional status, ventilation disorders, dilated heart cavities, greater risk of fatal vascular complications in patients with HP associated with hypertension.
- 30 April 2022
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 32 (2) , 171-180-180
Open AccessНуреrsensitivity pneumonitis combined with arterial hypertension: clinical, radiological, functional features
The aim of the study was to explore the clinical, radiological, functional indicators of hypersensitivity pneumonitis (HP) in combination with arterial hypertension, to assess the effect of these diseases on each other.Methods. The study included 50 patients with hypersensitivity pneumonitis (HP) and 49 patients with arterial hypertension (AH). The patients were divided into three groups. The main group included 24 patients with hypersensitivity pneumonitis combined with AH. The comparison group was 26 patients with HP without AH; the control group was 25 patients with arterial hypertension alone. Clinical symptoms, radiological findings, and results of instrumental tests were analyzed.Results. The intensity of clinical symptoms (shortness of breath, cough) was significantly higher in the main group than in the control and comparison groups. Exercise tolerance estimated from the six-minute walk test was significantly lower in the main group. The clinical status correlated with the functional testResults. Volumetric and velocity spirometry values tended to decrease more in the main group compared to the other two groups. The lung diffusion capacity was significantly lower in the group of patients with HP in combination with AH compared to the group of patients with hypertension only. A similar trend was observed when assessing the chest CT: significantly more pronounced changes were found in the main group. EchoCG showed a significant increase in pulmonary hypertension and volumes of the right heart in the main group compared to the group of patients with AH alone.Conclusion. The present study provides evidence of the greater intensity of respiratory symptoms, decreased functional status, ventilation disorders, dilated heart cavities, greater risk of fatal vascular complications in patients with HP associated with hypertension.
- 21 February 2022
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 32 (1) , 95-102
Patients with non-tuberculous mycobacteriosis in clinical practice
Incidence and prevalence of non-tuberculous mycobacteriosis (NTM) are recorded in many countries, but the rates vary. There are no official statistics on the prevalence and incidence of NTMs in the Russian Federation at the moment. The regulatory and expert clinical database for NTMs has not yet been developed. The aim of thе article is to share the experience of the Federal State Scientific Institution “Central Research Institute of Tuberculosis” (FSSI “CRIT”) in working with patients with NTMB over the past 7 years. Methods. The study included 190 patients with a confirmed diagnosis of NTMB who were treated at the FSSI “CRIT” in 2011 – 2018. Before the diagnosis of NTMB, all patients were followed for a long time by various specialists (pulmonologists, general practitioners) for various chronic respiratory diseases. NTMs were isolated from the diagnostic material by the culture method. The material was inoculated into a liquid medium in an automated BACTEC MGIT 960 system and into Levenshtein – Jensen dense medium until the culture growth was obtained. The HTM species was determined using DNA strips GenoType® Mycobacterium CM by Hain Lifescience (Germany). Results. More than half of the examined patients were registered with a phthisiatrician for various clinical forms of pulmonary tuberculosis (disseminated, fibro-cavernous, focal). In 85.6% of cases, no MBT DNA was found in the sputum and skin tests with recombinant tuberculosis antigen (Diaskintest®) were negative. Nevertheless, the changes in the lungs detected on the chest CT and even a single detection of acid-fast microorganisms (AFB) without typing led to an erroneous diagnosis of tuberculosis. In some patients (6.8%), a combination of pulmonary tuberculosis and NTMB was diagnosed. Bronchiectasis and COPD were the most common chronic nonspecific lung diseases. 66.7% of the patients had centrilobular foci characterized by the involvement of not only the bronchial wall but also the pulmonary vessels. NTMB resistance to a wide range of antibacterial drugs was determined in 118 patients (out of 190). The prolonged use of chemotherapy drugs revealed a wide range of drug intolerance. Side effects were handled in various ways: drug replacement (with consideration to the sensitivity), temporary withdrawal, and drug discontinuation. Conclusion. This work reflects the long-term experience of the FSSI “CRIT” staff with patients with NTMs, which can be used in creating national recommendations on NTMs.
- 21 February 2022
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 32 (1) , 95-102
Patients with non-tuberculous mycobacteriosis in clinical practice
Incidence and prevalence of non-tuberculous mycobacteriosis (NTM) are recorded in many countries, but the rates vary. There are no official statistics on the prevalence and incidence of NTMs in the Russian Federation at the moment. The regulatory and expert clinical database for NTMs has not yet been developed. The aim of thе article is to share the experience of the Federal State Scientific Institution “Central Research Institute of Tuberculosis” (FSSI “CRIT”) in working with patients with NTMB over the past 7 years. Methods. The study included 190 patients with a confirmed diagnosis of NTMB who were treated at the FSSI “CRIT” in 2011 – 2018. Before the diagnosis of NTMB, all patients were followed for a long time by various specialists (pulmonologists, general practitioners) for various chronic respiratory diseases. NTMs were isolated from the diagnostic material by the culture method. The material was inoculated into a liquid medium in an automated BACTEC MGIT 960 system and into Levenshtein – Jensen dense medium until the culture growth was obtained. The HTM species was determined using DNA strips GenoType® Mycobacterium CM by Hain Lifescience (Germany). Results. More than half of the examined patients were registered with a phthisiatrician for various clinical forms of pulmonary tuberculosis (disseminated, fibro-cavernous, focal). In 85.6% of cases, no MBT DNA was found in the sputum and skin tests with recombinant tuberculosis antigen (Diaskintest®) were negative. Nevertheless, the changes in the lungs detected on the chest CT and even a single detection of acid-fast microorganisms (AFB) without typing led to an erroneous diagnosis of tuberculosis. In some patients (6.8%), a combination of pulmonary tuberculosis and NTMB was diagnosed. Bronchiectasis and COPD were the most common chronic nonspecific lung diseases. 66.7% of the patients had centrilobular foci characterized by the involvement of not only the bronchial wall but also the pulmonary vessels. NTMB resistance to a wide range of antibacterial drugs was determined in 118 patients (out of 190). The prolonged use of chemotherapy drugs revealed a wide range of drug intolerance. Side effects were handled in various ways: drug replacement (with consideration to the sensitivity), temporary withdrawal, and drug discontinuation. Conclusion. This work reflects the long-term experience of the FSSI “CRIT” staff with patients with NTMs, which can be used in creating national recommendations on NTMs.